Chronic daily headache: long-term prognosis following inpatient treatment with repetitive IV DHE

Headache. 1992 Oct;32(9):439-45. doi: 10.1111/j.1526-4610.1992.hed3209439.x.


We retrospectively studied the long-term (2-year) outcome of 50 consecutive patients admitted to our inpatient headache program because of chronic daily headache (CDH) associated with the overuse of analgesics, ergotamine, or both. They had been detoxified, given repetitive intravenous dihydroergotamine (IV DHE) and prophylactic medications as part of the program, and had become headache-free on this regimen. At the time of admission, 37 of the 50 patients had transformed migraine (TM), 12 had new daily persistent headache (NDPH), and 1 had chronic tension-type headache; 29 of the patients with TM, 7 of those with NDPH, and the single patient with chronic tension-type headache had coexistent migraine. Substances abused, alone or in combination, included: caffeine in 39 patients (av. 441 mg/d), acetaminophen in 32 (av. 2187 mg/d), aspirin in 24 (av. 1807 mg/d), ibuprofen in 9 (av. 1156 mg/d), narcotics in 7 (av. 10.1 mg morphine equivalents/d) and ergotamine in 11 (av. 2.3 mg/d). Twenty patients were using preventive medication at the time of admission. Follow-up evaluations were performed at 3, 6, 12, and 24 months after discharge. Forty-three patients were analyzed at 3 months. Of these, 44% had an excellent or good result and 28% a fair result; 3 were overusing analgesics. At 24 months, 39 patients were analyzed: 59% had a good or excellent result and 28% a fair result; 5 were overusing analgesics, 4 of whom were doing poorly.(ABSTRACT TRUNCATED AT 250 WORDS)

MeSH terms

  • Adult
  • Aged
  • Chronic Disease
  • Dihydroergotamine / administration & dosage*
  • Dihydroergotamine / therapeutic use
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Headache / chemically induced
  • Headache / drug therapy*
  • Hospitalization*
  • Humans
  • Injections, Intravenous
  • Interviews as Topic
  • Male
  • Middle Aged
  • Prognosis
  • Substance-Related Disorders / complications
  • Time Factors


  • Dihydroergotamine